Lipomics Technologies announces agreement with GlaxoSmithKline for access to lipid metabolite research and interpretation
Lipomics Technologies has announced that it has signed a research collaboration and option agreement with GlaxoSmithKline for drug discovery and diagnostic development.
Lipomics will evaluate the effects of drug compounds on metabolism and establish the mechanism of drug response using TrueMass lipid analysis and customised Surveyor and Insight graphical representations of lipid metabolism.
The research will involve discovery research and clinical trials of promising drugs with a focus on metabolic and cardiovascular diseases.
Financial details of the agreement were not disclosed.
"Lipomics has an extremely advanced knowledge of lipid metabolism," said Tom Anderson, Lipomics CEO.
"The information we provide assists in the understanding of the effects of specific drug candidates on lipid metabolism.
"This can help inform the decision making process in early drug discovery".
This collaboration will also include efforts to help identify early biomarkers of drug response and disease progression, or to identify patients likely to have adverse drug responses, thereby enhancing the efficiency and decision making process of the expensive drug discovery process.
